Study of plasma protein C and inflammatory pathways: Biomarkers for dimethylnitrosamine-induced liver fibrosis in rats

Joy K. Saha, Jinqi Xia, George Sandusky, Yun Fei Chen, Bruce Gerlitz, Brian Grinnell, Joseph A. Jakubowski

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The present investigation was designed to identify potential biomarker(s) and assess the involvement of inflammatory pathway in dimethylnitrosamine (DMN)-induced liver fibrosis in rats. Following DMN-treatment (10 mg/ml/kg, i.p., given three consecutive days each week for 4 weeks) body and liver weights were significantly decreased concurrent with increasing severity of liver damage assessed by bridging fibrosis, a histopathologic assessment and characteristic of human liver disease. Protein C along with albumin, C-reactive-protein (CRP), haptoglobin and total protein were significantly reduced and correlated with changes in liver histopathology. Biochemical markers of liver functions were significantly increased and correlated with changes in liver histopathology and plasma levels of protein C. Soluble intracellular-adhesion-molecule-1 (sICAM-1) levels were increased significantly but were poorly correlated with histopathology and protein C levels. Inflammatory chemokines and other analytes, monocyte-chemoattractant-protein-1 and 3 (MCP-1 and MCP-3), macrophage-colony-stimulating-factor (M-CSF) were significantly increased during the disease progression, whereas macrophage-derived-chemokine (MDC) and CRP were significantly suppressed. Circulating neutrophils and monocytes were also increased along with disease progression. The differential changes in sICAM-1, hyaluronic acid, gamma-glutamyltranspeptidase (GGT), neutrophil and other inflammatory chemokines suggest the involvement of inflammatory pathways in DMN-induced liver fibrosis. In conclusion, the progressive changes in protein C along with other noninvasive biochemical parameters whose levels were significantly correlated with disease progression may serve as biomarkers for pharmacological assessment of targeted therapy for liver fibrosis.

Original languageEnglish (US)
Pages (from-to)158-167
Number of pages10
JournalEuropean Journal of Pharmacology
Volume575
Issue number1-3
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Dimethylnitrosamine
Protein C
Liver Cirrhosis
Blood Proteins
Biomarkers
Liver
Disease Progression
Chemokines
C-Reactive Protein
Pharmacological Biomarkers
Chemokine CCL7
Neutrophils
Chemokine CCL22
Haptoglobins
Macrophage Colony-Stimulating Factor
Chemokine CCL2
Hyaluronic Acid
Liver Diseases
Monocytes
Albumins

Keywords

  • Biomarker
  • Chemokine
  • Dimethylnitrosamine
  • Inflammation
  • Liver enzyme
  • Liver fibrosis
  • Liver histopathology
  • Protein C
  • sICAM-1

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Study of plasma protein C and inflammatory pathways : Biomarkers for dimethylnitrosamine-induced liver fibrosis in rats. / Saha, Joy K.; Xia, Jinqi; Sandusky, George; Chen, Yun Fei; Gerlitz, Bruce; Grinnell, Brian; Jakubowski, Joseph A.

In: European Journal of Pharmacology, Vol. 575, No. 1-3, 01.12.2007, p. 158-167.

Research output: Contribution to journalArticle

Saha, Joy K. ; Xia, Jinqi ; Sandusky, George ; Chen, Yun Fei ; Gerlitz, Bruce ; Grinnell, Brian ; Jakubowski, Joseph A. / Study of plasma protein C and inflammatory pathways : Biomarkers for dimethylnitrosamine-induced liver fibrosis in rats. In: European Journal of Pharmacology. 2007 ; Vol. 575, No. 1-3. pp. 158-167.
@article{24d70453aba44bce9a1e6e045dd87973,
title = "Study of plasma protein C and inflammatory pathways: Biomarkers for dimethylnitrosamine-induced liver fibrosis in rats",
abstract = "The present investigation was designed to identify potential biomarker(s) and assess the involvement of inflammatory pathway in dimethylnitrosamine (DMN)-induced liver fibrosis in rats. Following DMN-treatment (10 mg/ml/kg, i.p., given three consecutive days each week for 4 weeks) body and liver weights were significantly decreased concurrent with increasing severity of liver damage assessed by bridging fibrosis, a histopathologic assessment and characteristic of human liver disease. Protein C along with albumin, C-reactive-protein (CRP), haptoglobin and total protein were significantly reduced and correlated with changes in liver histopathology. Biochemical markers of liver functions were significantly increased and correlated with changes in liver histopathology and plasma levels of protein C. Soluble intracellular-adhesion-molecule-1 (sICAM-1) levels were increased significantly but were poorly correlated with histopathology and protein C levels. Inflammatory chemokines and other analytes, monocyte-chemoattractant-protein-1 and 3 (MCP-1 and MCP-3), macrophage-colony-stimulating-factor (M-CSF) were significantly increased during the disease progression, whereas macrophage-derived-chemokine (MDC) and CRP were significantly suppressed. Circulating neutrophils and monocytes were also increased along with disease progression. The differential changes in sICAM-1, hyaluronic acid, gamma-glutamyltranspeptidase (GGT), neutrophil and other inflammatory chemokines suggest the involvement of inflammatory pathways in DMN-induced liver fibrosis. In conclusion, the progressive changes in protein C along with other noninvasive biochemical parameters whose levels were significantly correlated with disease progression may serve as biomarkers for pharmacological assessment of targeted therapy for liver fibrosis.",
keywords = "Biomarker, Chemokine, Dimethylnitrosamine, Inflammation, Liver enzyme, Liver fibrosis, Liver histopathology, Protein C, sICAM-1",
author = "Saha, {Joy K.} and Jinqi Xia and George Sandusky and Chen, {Yun Fei} and Bruce Gerlitz and Brian Grinnell and Jakubowski, {Joseph A.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/j.ejphar.2007.07.052",
language = "English (US)",
volume = "575",
pages = "158--167",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Study of plasma protein C and inflammatory pathways

T2 - Biomarkers for dimethylnitrosamine-induced liver fibrosis in rats

AU - Saha, Joy K.

AU - Xia, Jinqi

AU - Sandusky, George

AU - Chen, Yun Fei

AU - Gerlitz, Bruce

AU - Grinnell, Brian

AU - Jakubowski, Joseph A.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - The present investigation was designed to identify potential biomarker(s) and assess the involvement of inflammatory pathway in dimethylnitrosamine (DMN)-induced liver fibrosis in rats. Following DMN-treatment (10 mg/ml/kg, i.p., given three consecutive days each week for 4 weeks) body and liver weights were significantly decreased concurrent with increasing severity of liver damage assessed by bridging fibrosis, a histopathologic assessment and characteristic of human liver disease. Protein C along with albumin, C-reactive-protein (CRP), haptoglobin and total protein were significantly reduced and correlated with changes in liver histopathology. Biochemical markers of liver functions were significantly increased and correlated with changes in liver histopathology and plasma levels of protein C. Soluble intracellular-adhesion-molecule-1 (sICAM-1) levels were increased significantly but were poorly correlated with histopathology and protein C levels. Inflammatory chemokines and other analytes, monocyte-chemoattractant-protein-1 and 3 (MCP-1 and MCP-3), macrophage-colony-stimulating-factor (M-CSF) were significantly increased during the disease progression, whereas macrophage-derived-chemokine (MDC) and CRP were significantly suppressed. Circulating neutrophils and monocytes were also increased along with disease progression. The differential changes in sICAM-1, hyaluronic acid, gamma-glutamyltranspeptidase (GGT), neutrophil and other inflammatory chemokines suggest the involvement of inflammatory pathways in DMN-induced liver fibrosis. In conclusion, the progressive changes in protein C along with other noninvasive biochemical parameters whose levels were significantly correlated with disease progression may serve as biomarkers for pharmacological assessment of targeted therapy for liver fibrosis.

AB - The present investigation was designed to identify potential biomarker(s) and assess the involvement of inflammatory pathway in dimethylnitrosamine (DMN)-induced liver fibrosis in rats. Following DMN-treatment (10 mg/ml/kg, i.p., given three consecutive days each week for 4 weeks) body and liver weights were significantly decreased concurrent with increasing severity of liver damage assessed by bridging fibrosis, a histopathologic assessment and characteristic of human liver disease. Protein C along with albumin, C-reactive-protein (CRP), haptoglobin and total protein were significantly reduced and correlated with changes in liver histopathology. Biochemical markers of liver functions were significantly increased and correlated with changes in liver histopathology and plasma levels of protein C. Soluble intracellular-adhesion-molecule-1 (sICAM-1) levels were increased significantly but were poorly correlated with histopathology and protein C levels. Inflammatory chemokines and other analytes, monocyte-chemoattractant-protein-1 and 3 (MCP-1 and MCP-3), macrophage-colony-stimulating-factor (M-CSF) were significantly increased during the disease progression, whereas macrophage-derived-chemokine (MDC) and CRP were significantly suppressed. Circulating neutrophils and monocytes were also increased along with disease progression. The differential changes in sICAM-1, hyaluronic acid, gamma-glutamyltranspeptidase (GGT), neutrophil and other inflammatory chemokines suggest the involvement of inflammatory pathways in DMN-induced liver fibrosis. In conclusion, the progressive changes in protein C along with other noninvasive biochemical parameters whose levels were significantly correlated with disease progression may serve as biomarkers for pharmacological assessment of targeted therapy for liver fibrosis.

KW - Biomarker

KW - Chemokine

KW - Dimethylnitrosamine

KW - Inflammation

KW - Liver enzyme

KW - Liver fibrosis

KW - Liver histopathology

KW - Protein C

KW - sICAM-1

UR - http://www.scopus.com/inward/record.url?scp=35348839103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348839103&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2007.07.052

DO - 10.1016/j.ejphar.2007.07.052

M3 - Article

C2 - 17719030

AN - SCOPUS:35348839103

VL - 575

SP - 158

EP - 167

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -